India is struggling with the twin epidemics of diabetes and weight issues, holding the second position globally in the former and third in the latter. Despite multiple advancements with therapies that offer glycemic control and weight benefits, there has remained a gap for a comprehensive drug for the management of "diabesity." Semaglutide, since its global approval in 2017, has become a blockbuster, owing to the popularity of "Ozempic." While Ozempic has been traditionally approved for glycemic control in type 2 diabetes mellitus (T2DM), it does offer significant other benefits powerful weight loss, cardiovascular benefits, renal protection benefits, and functional improvement in peripheral arterial disease. The drug is approved in India for first-line use in adults with T2DM as an adjunct to diet and exercise. The long use of semaglutide globally and in India has ensured adequate data on efficacy and safety, ensuring confidence and trust. Gastrointestinal side effects are the most common adverse events seen with the molecule, as with other GLP-1 drugs. This review highlights the global clinical data and practicalities of the use of Ozempic in diabesity in the Indian context.
Obstructive sleep apnea is a common yet under-recognized condition. 80% of sleep apnea cases go undiagnosed, and it is a common contributor to sudden death. Therefore, a simple and sensitive screening tool is the need of the hour. We developed a simple, more convenient, and user-friendly 3-question screening tool to identify individuals at risk of obstructive sleep apnea.
Type 1 diabetes (T1D) management in schools requires properly trained staff capable of glucose monitoring, insulin delivery, and blood glucose management. Our study assessed the management practices and challenges related to T1D among school-going children and youth to identify gaps and propose strategies for effective diabetes care and support in the school environment. Using a quantitative, cross-sectional design, we collected data through an anonymous questionnaire distributed via healthcare professionals using convenience and snowball sampling techniques. Responses were received from 335 youth with T1D (n = 160, 47.8
[This corrects the article DOI: 10.1016/j.obpill.2026.100296.].
Abstract Glucagon-Like Peptide-1 (GLP-1) and its analogues have therapeutic potential in treating various conditions like Type 2 diabetes (T2D) and obesity, with a focus on their neuroprotective and anti-inflammatory properties in ocular diseases. GLP-1, a hormone produced in the intestinal mucosa and brain, enhances insulin secretion and lowers blood glucose levels. GLP-1 receptor agonists (GLP-1RAs) are effective in treating T2D mellitus (T2DM) and obesity, and have shown potential in treating heart failure (preserved ejection fraction), diabetic kidney disease, and neurodegenerative diseases like Parkinson’s and Alzheimer’s. In ocular diseases, GLP-1RAs have demonstrated protective effects against diabetic retinopathy and glaucoma by reducing inflammation, preventing retinal cell loss, and maintaining vascular integrity. Semaglutide, a GLP-1RA, is used for T2DM and obesity treatment, showing significant weight reduction and glycemic control. This review aims to a deeper understanding of how GLP-1RAs, including semaglutide, offer promising therapeutic benefits for both metabolic and ocular health conditions.
